Stockreport

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque  ProMIS on track to complete [Read more]